Human BRAK/CXCL14 (Breast and Kidney Expressed Chemokine) CLIA Kit
The Human BRAK/CXCL14 (Breast- and Kidney-Expressed Chemokine) CLIA Kit (HUES00401) is a cutting-edge assay designed for the quantitative detection of BRAK/CXCL14 levels in human samples such as serum, plasma, and tissue homogenates. This kit offers exceptional sensitivity and specificity, ensuring accurate and reproducible results for a variety of research applications.BRAK/CXCL14 is a chemokine known for its role in regulating immune responses and cell migration, particularly in the context of breast and kidney tissue.
Dysregulation of BRAK/CXCL14 has been linked to various diseases, making it a valuable biomarker for studying these conditions and developing potential therapeutic interventions.With the Human BRAK/CXCL14 CLIA Kit, researchers can gain valuable insights into the role of this important chemokine in health and disease, paving the way for advancements in clinical diagnostics and treatment strategies.
Product Name:
Human BRAK/CXCL14 (Breast and Kidney Expressed Chemokine) CLIA Kit
SKU:
HUES00401
Target:
Human BRAK/CXCL14 (Breast and Kidney Expressed Chemokine)
Size:
96T
Assay type:
Sandwich-CLIA
Assay time:
3.5h
Sensitivity:
18.75 pg/mL
Detection range:
31.25-2000 pg/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
CLIA Plate
8 wells x 3 strips
8 wells x 12 strips
-20°C, 6 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 6 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 6 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent A
1 vial, 5 mL
1 vial, 5 mL
4°C (shading light)
Substrate Reagent B
1 vial, 5 mL
1 vial, 5 mL
Desiccant
1
1
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human BRAK/CXCL14. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human BRAK/CXCL14 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human BRAK/CXCL14, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human BRAK/CXCL14. You can calculate the concentration of Human BRAK/CXCL14 in the samples by comparing the RLU value of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
86-102
99-116
100-112
Average (%)
93
108
106
1:4
Range (%)
85-99
100-112
99-113
Average (%)
91
106
105
1:8
Range (%)
96-113
84-99
97-111
Average (%)
104
91
103
1:16
Range (%)
83-95
93-104
90-100
Average (%)
90
99
95
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
94-106
100
EDTA plasma (n=5)
96-108
101
Cell culture media (n=5)
98-112
104
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20.0
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
103.36
176.33
819.52
106.88
177.41
873.36
Standard deviation
10.36
12.84
61.55
12.48
16.37
55.72
C V (%)
10.02
7.28
7.51
11.68
9.23
6.38
Sample type &Sample volume:
serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 15%.
Application:
This CLIA kit applies to the in vitro quantitative determination of Human BRAK/CXCL14 concentrations in serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human BRAK/CXCL14 in samples. No significant cross-reactivity or interference between Human BRAK/CXCL14 and analogues was observed.
